Pharmaron (康龙化成) Post-IPO: A/H Convergence Post Connect Inclusion Supports A Trade
Pharmaron, the second-largest contract research organization (CRO) in China, was listed in Hong Kong on November 28th. The deal was anchored by a...
503 Views
Pharmaron Beijing: Trading Debut, Valuation Scenario Analysis
Pharmaron Beijing Co Ltd-H (3759 HK) is a global contract research organisation (CRO) and is one of the top three drug discovery service providers...
415 Views
Pharmaron Beijing IPO: H-Share Valuation Enticing
Pharmaron Beijing Co Ltd-H (3759 HK) is a global contract research organisation (CRO) and is one of the top three drug discovery service providers...
586 Views
Pharmaron (康龙化成) A+H: Decent H/A Discount and Cornerstone Line-Up
Pharmaron, the secondly largest CRO based in China, launched book building today to raise up to USD 588 million to list in Hong Kong. In our...
567 Views
Pharmaron (康龙化成) A+H Listing: 3Q2019 Numbers and Thoughts on Valuation
Pharmaron, a leading contract research company, is looking to list in Hong Kong by raising up to USD 600 million. In our previous note, we have...
552 Views